SCHEMBL3715136

SCHEMBL3715136

CON(C)S(=O)(=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.58
ALDH1A1 P00352 1/20 0.58
CA12 O43570 2/20 0.54
CA2 P00918 2/20 0.54
CA9 Q16790 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
RAB9A P51151 1/20 0.54
SLC22A6 Q4U2R8 1/20 0.54
SLC22A8 Q8TCC7 1/20 0.54
ABCC2 Q92887 1/20 0.54
SLC22A12 Q96S37 1/20 0.54
UGT1A7 Q9HAW7 1/20 0.54
SLC22A11 Q9NSA0 1/20 0.54
TAS2R14 Q9NYV8 10/20 0.53
PTGES O14684 1/20 0.49
TAS2R8 Q9NYW2 1/20 0.49
CXCR3 P49682 1/20 0.49
MEN1 O00255 1/20 0.49
CA1 P00915 1/20 0.48
CA3 P07451 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17290928 0.86 KMT2A (0.47) KMT2AALDH1A1CA12CA2CA9
SCHEMBL8812626 0.84 CA2 (0.52) KMT2AALDH1A1CA12CA2CA9
SCHEMBL17290279 0.82 ALDH1A1 (0.42) KMT2AALDH1A1CA12CA2CA9
SCHEMBL17290742 0.81 TAS2R14 (0.42) KMT2AALDH1A1CA12CA2CA9
SCHEMBL34672 0.81 ALDH1A1 (0.66) KMT2AALDH1A1CA12CA2CA9
SCHEMBL3938764 0.80 SMN1; SMN2 (0.53) KMT2AALDH1A1CA2SMN1; SMN2MEN1
SCHEMBL17290525 0.79 MEN1 (0.41) KMT2AALDH1A1CA12CA9SMN1; SMN2
SCHEMBL3566251 0.79 APOBEC3G (0.50) KMT2AALDH1A1CA12CA9MEN1
SCHEMBL17290302 0.77 FGFR1 (0.39) ALDH1A1CA12CA2CA9SMN1; SMN2
SCHEMBL3642059 0.76 CA12 (0.59) KMT2AALDH1A1CA12CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using MTOR, RICTOR, RPTOR KMT2A 3940/4885ALDH1A1 3391/4885CA12 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.